PMWC Interview with Data4Cure’s Janusz Dutkowski

In a recent interview featured on the PMWC Blog, our CEO and co-founder, Janusz Dutkowski, Ph.D., considers how machine learning and systems biology are transforming biomedical research and discusses the challenges in pharmaceutical R&D addressed by the Data4Cure Platform.

Learn more from the PMWC Blog:

PMWC Interview with Janusz Dutkowski, Ph.D., Co-founder & CEO, Data4Cure

Please join Data4Cure for our two presentations at the Precision Medicine World Conference (PMWC) that will take place in Silicon Valley on January 22-24, 2018. This world’s leading precision medicine conference attracts recognized leaders, top global researchers and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors. Since 2009, recognized as a vital cornerstone for all constituents of the healthcare and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology (e.g. DNA sequencing technology), clinical implementation (e.g. cancer and beyond), research, and in all aspects related to the regulatory sectors.

Data4Cure featured in GEN

Genetic Engineering & Biotechnology News (GEN) featured Data4Cure, Inc. in the article Machines Learn to Sift Big Biodata by Kristen Slawinski, Ph.D. GEN is the premier biotech publication since its launch in 1981.

Here are some highlights from the article:

“As more relevant connections are made among biological data, more meaningful conclusions can be made to drive drug discovery and development. Large datasets are a starting point for integrating and connecting data; however, there is also critical biological information that exists discreetly buried within millions of scientific publications. Accessing and linking this information requires an intelligence beyond human processing.”

“Data4Cure’s all-inclusive bioinformatics platform, the Biomedical Intelligence Cloud, is powered by a dynamic graphical knowledge base named CURIE, which uses advanced machine learning to automatically mine molecular datasets as well as published texts.”

“The robust network of biological information contained within the Biomedical Intelligence Cloud allows users to visualize their favorite biological molecule at a systems level. Even more impressive is the way in which the data can be analyzed to stratify patients into disease subtypes, a capability that can lead to predictions of therapeutic efficacy.

For example, a pathway activity analysis using patient expression data can identify immune cell-infiltrated and noninfiltrated tumor subtypes and associates them with specific genomic alterations. This information can then be used in immuno-oncology clinical trial planning by linking subtypes to treatment response.

Use of Data4Cure’s bioinformatic platform ensures an informed drug development plan which is beneficial for everyone.”

Read the full article here.

Data4Cure’s AI-Powered Biomedical Intelligence Cloud Features New Tools for Immuno-Oncology

La Jolla, CAJanuary 24, 2017 /PRNewswire/ — Data4Cure, Inc. today announced a series of updates and new case studies using its Biomedical Intelligence® Cloud – a semantic data-driven discovery platform designed to continuously grow knowledge from a multitude of genomic, molecular and clinical data that are accumulating rapidly in the field. These updates were presented at a session hosted by Data4Cure at the Precision Medicine World Conference (PMWC) in Mountain View, CA.

Watch videos from the PMWC session here:

The company’s Biomedical Intelligence® Cloud now includes new tools for immune-oncology research, improved applications for mapping the molecular basis of disease, and a new multidimensional version of the company’s molecular stratification engine.

Data4Cure’s platform is powered by CURIE™, a dynamic biomedical knowledge graph that is continuously updated with information dynamically extracted from a variety of data sources. Cross-referencing tens of thousands of datasets and bioinformatics analyses, literature, clinical trials and external databases, CURIE provides immediate data-driven answers to over 100 million biomedical questions.

CURIE understands biology,” said Janusz Dutkowski, Ph.D., CEO, Data4Cure, who chaired the PMWC session. “It combines advanced machine learning, systems biology and semantic search capabilities providing a new way to make discoveries. Our platform allows biological and clinical researchers to leverage diverse datasets to discover relationships between entities in a molecular system, and uncover how these entities and relations are affected by the disease and environment, and how they respond to drug interventions.”

CURIE is used by multiple applications running on Data4Cure’s Biomedical Intelligence Cloud. One of these presented in the update is the Disease Maps application which leverages a plethora of public and proprietary data to create up-do-date molecular maps for over 500 disease conditions including multiple cancer types, Alzheimer’s disease, Rheumatoid arthritis, diabetes, and other metabolic, immunological and neurological disorders.

The newest additions to Biomedical Intelligence Cloud platform include tools for immune-oncology research that Data4Cure has been testing with selected pharmaceutical partner companies. “These tools include algorithms for inferring immune cell types infiltrating tumors as well as systems biology tools for interrogating immune pathway activities associated with specific diseases subtypes,” said Roy Ronen, Ph.D., VP, Computational Biology at Data4Cure. The new tools are integrated with CURIE and other applications including the stratification and pathway analysis tools.

The platform also includes a redesigned network-based stratification engine which uses network maps along with genetic, epigenetic and transcriptional evidence to identify disease subtypes that are directly tied to the network and pathway-level activities and aberrations, and can be further associated with predicted sensitivity or resistance to selected drugs. In oncology applications the stratification process can now be informed by immune-infiltrate profiles inferred by the platform.

Data4Cure @ PMWC 2017

Updates were also introduced to the Multiscale Pathway Maps which combine with the Stratifier to analyze subtype-specific pathway activities, including among the immune pathway component. The updated Disease Maps application –   providing an integrative, data-driven view of a disease networks and drivers – features enhanced omics integration at the pathway-level and annotates maps with detailed information about drug targets, approved therapies and clinical trials.

Data4Cure Disease Maps

Launched in 2016, the Biomedical Intelligence Cloud has attracted customers and partners across some of the largest global pharmaceutical companies and leading research institutes. “We are very excited to work with some of the best research groups in the industry and academia,” said Dutkowski. “By dramatically accelerating the access to data-driven knowledge and uncovering non-obvious connections hidden in millions of datasets, scientific papers and clinical trials we can really start to turn data into cures.”

Learn more at www.data4cure